MILAN, Italy and NEW YORK , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that management will be participating in
MILAN, Italy and NEW YORK , Dec. 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A . (Nasdaq: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™,
MILAN, Italy and NEW YORK , Dec. 14, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™, announced today the
MILAN (Italy)/NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno- gene therapy for cancer (Temferon™), announced today that it will be presenting updated preliminary Phase I/II clinical data on
MILAN (Italy)/NEW YORK (NY, USA) Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that it has filed a registration statement on Form F-1 (the “Registration Statement”)
Gaurav Shah, Brad Loncar and Alec Ross appointed as strategic advisors Barbara Regonini joins recently hired CFO, Richard Slansky, completing senior financial management team MILAN, Italy and NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company
MILAN (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced the appointment of four renowned experts in oncology as new members of its Scientific Advistory Board
Data presented at the 2021 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting MILAN (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of an investigational hematopoietic stem progenitor cell immuno-gene therapy for
MILAN (Italy) / NEW YORK (NY, USA) – Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced it will be presenting at several upcoming scientific congresses in May and June.
MILAN (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announces that Richard Slansky is appointed as Chief Financial Officer (“CFO”) and proposes Anthony Marucci as
